$TCRT
Alaunos Therapeutics, Inc.

2019 Q3 Form 10-Q Financial Statement

#000119312519216056 Filed on August 08, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2019 Q2 2019 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.810M $4.760M $4.150M
YoY Change 11.6% -2.66% -32.63%
% of Gross Profit
Research & Development $8.641M $9.998M $9.476M
YoY Change 4.57% 33.5% -6.94%
% of Gross Profit
Depreciation & Amortization $150.0K $160.0K $140.0K
YoY Change 0.0% 14.29% 19.66%
% of Gross Profit
Operating Expenses $13.45M $14.75M $13.62M
YoY Change 6.98% 19.19% -16.65%
Operating Profit -$13.45M -$14.75M -$13.62M
YoY Change 6.98% 19.19% -15.9%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
% of Operating Profit
Other Income/Expense, Net $203.0K $133.0K $187.0K
YoY Change 35.33% -18.9% 26.35%
Pretax Income -$74.00M -$14.62M -$13.43M
YoY Change 487.77% 21.53% -16.17%
Income Tax
% Of Pretax Income
Net Earnings -$74.00M -$14.62M -$13.43M
YoY Change 296.57% -16.42% -36.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.43 -$0.09 -$0.08
Diluted Earnings Per Share -$0.43 -$0.09 -$0.08
COMMON SHARES
Basic Shares Outstanding 162.6M 162.4M 162.3M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q3 2019 Q2 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $88.40M $43.60M $51.50M
YoY Change 178.86% 7.92% 0.78%
Cash & Equivalents $88.42M $43.56M $51.49M
Short-Term Investments
Other Short-Term Assets $23.70M $20.80M $21.80M
YoY Change 64.58% 74.79% 3.81%
Inventory
Prepaid Expenses
Receivables $3.400M $1.500M $900.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $115.6M $65.86M $74.09M
YoY Change 145.12% 24.28% 2.74%
LONG-TERM ASSETS
Property, Plant & Equipment $828.0K $877.0K $967.0K
YoY Change -38.39% -34.16% -22.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $109.0K $4.869M $6.724M
YoY Change -99.4% -77.8% -51.88%
Total Long-Term Assets $2.350M $7.314M $9.410M
YoY Change -88.03% -68.73% -38.68%
TOTAL ASSETS
Total Short-Term Assets $115.6M $65.86M $74.09M
Total Long-Term Assets $2.350M $7.314M $9.410M
Total Assets $117.9M $73.17M $83.50M
YoY Change 76.57% -4.2% -4.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $926.0K $941.0K $859.0K
YoY Change -27.03% 60.03% 41.75%
Accrued Expenses $9.573M $8.799M $6.836M
YoY Change 2.09% 1.57% -23.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.18M $10.40M $8.339M
YoY Change -81.43% 11.66% -17.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $800.0K $900.0K
YoY Change -76.92% -98.46% -98.25%
Total Long-Term Liabilities $600.0K $800.0K $900.0K
YoY Change -76.92% -98.46% -98.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.18M $10.40M $8.339M
Total Long-Term Liabilities $600.0K $800.0K $900.0K
Total Liabilities $11.82M $11.18M $9.287M
YoY Change -81.17% -81.73% -84.92%
SHAREHOLDERS EQUITY
Retained Earnings -$668.4M -$594.4M -$579.8M
YoY Change -12.2% -20.6% -21.29%
Common Stock $774.5M $656.4M $654.0M
YoY Change 28.06% 7.71% 6.61%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $106.1M $62.00M $74.22M
YoY Change
Total Liabilities & Shareholders Equity $117.9M $73.17M $83.50M
YoY Change 76.57% -4.2% -4.53%

Cashflow Statement

Concept 2019 Q3 2019 Q2 2019 Q1
OPERATING ACTIVITIES
Net Income -$74.00M -$14.62M -$13.43M
YoY Change 296.57% -16.42% -36.45%
Depreciation, Depletion And Amortization $150.0K $160.0K $140.0K
YoY Change 0.0% 14.29% 19.66%
Cash From Operating Activities -$10.93M -$8.090M -$10.23M
YoY Change 28.44% -20.45% -46.03%
INVESTING ACTIVITIES
Capital Expenditures $100.0K $70.00K $10.00K
YoY Change -41.18% -69.57% -93.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$100.0K -$70.00K -$10.00K
YoY Change -41.18% -69.57% -93.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 55.89M 230.0K 0.000
YoY Change -174.19% -100.0%
NET CHANGE
Cash From Operating Activities -10.93M -8.090M -10.23M
Cash From Investing Activities -100.0K -70.00K -10.00K
Cash From Financing Activities 55.89M 230.0K 0.000
Net Change In Cash 44.86M -7.930M -10.24M
YoY Change -616.82% -25.96% -48.37%
FREE CASH FLOW
Cash From Operating Activities -$10.93M -$8.090M -$10.23M
Capital Expenditures $100.0K $70.00K $10.00K
Free Cash Flow -$11.03M -$8.160M -$10.24M
YoY Change 27.07% -21.54% -46.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1097000
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
877000
CY2019Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
130000
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
128000
CY2019Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4869000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9541000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43563000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61729000
CY2019Q2 us-gaap Assets
Assets
73173000
CY2018Q4 us-gaap Assets
Assets
95051000
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
10400000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9483000
CY2019Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
656216000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
651732000
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
162000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
161000
CY2019Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20836000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20692000
CY2019Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
1460000
CY2018Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1864000
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
941000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
707000
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8799000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8763000
CY2019Q2 us-gaap Assets Current
AssetsCurrent
65859000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
84285000
CY2019Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Liabilities
Liabilities
11178000
CY2018Q4 us-gaap Liabilities
Liabilities
9487000
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73173000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95051000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
13000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
4000
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-594383000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-566329000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
61995000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
133000
CY2018Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
164000
CY2018Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
183000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14620000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-12031000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-14753000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12378000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
320000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
312000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28374000
us-gaap Operating Income Loss
OperatingIncomeLoss
-28574000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162477963
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142379770
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
162477963
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142379770
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9998000
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7489000
CY2018Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
5462000
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14620000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1275000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17493000
us-gaap Net Income Loss
NetIncomeLoss
-28054000
us-gaap Net Income Loss
NetIncomeLoss
-28051000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
10582000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28054000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-38633000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4755000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4889000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
14753000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
12378000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19474000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17672000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8900000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11048000
us-gaap Operating Expenses
OperatingExpenses
28374000
us-gaap Operating Expenses
OperatingExpenses
28720000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-96806000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
-123149000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
85564000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
74216000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1799000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5370000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1711000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
-139235000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3255000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
211000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-146000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-74000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
61729000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71335000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43563000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40793000
us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
17000
us-gaap Depreciation
Depreciation
296000
us-gaap Depreciation
Depreciation
255000
us-gaap Share Based Compensation
ShareBasedCompensation
4255000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-404000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
645000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
144000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7892000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-4672000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
234000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3829000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
36000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1245000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
77000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
376000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-77000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-376000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18166000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30542000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
8447000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18319000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-29131000
CY2017 ziop License Agreement Commencement Date
LicenseAgreementCommencementDate
2015-05
CY2019Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1799000
CY2018Q2 us-gaap Share Based Compensation
ShareBasedCompensation
1711000
us-gaap Share Based Compensation
ShareBasedCompensation
5370000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
199422
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
198000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
205500
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5277085
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1695755
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1562833
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5077591
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2378158
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3099935
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.24
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.54
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.14
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M27D
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12463000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.90
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y11M4D
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4220000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.15
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y11M4D
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
88000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4069982
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
600000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
240000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
370000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
47256724
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26071564
ziop Research And Development Expense Related To Joint Venture
ResearchAndDevelopmentExpenseRelatedToJointVenture
35000000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0189
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0242
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0266
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0291
CY2018Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7268
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7885
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8148
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8166
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
332416
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.95
CY2018 ziop Related Party Transaction Expenses From Transactions With Related Party Advisory Fees
RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyAdvisoryFees
2000000
us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-8131000
CY2019Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
660000
CY2019Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
778000
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1438000
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
160789272
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
141017898
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
160718313
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
140935964
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-2000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
230000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1035000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-33000
ziop Compensation Paid In Common Stock Gross
CompensationPaidInCommonStockGross
1000000
CY2019Q1 ziop Lessee Operating Lease Monthly Average Rental Payment
LesseeOperatingLeaseMonthlyAverageRentalPayment
2000
CY2019Q2 us-gaap Security Deposit
SecurityDeposit
2000
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
182000
CY2018Q2 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
200000
CY2019Q2 us-gaap Lease Cost
LeaseCost
182000
us-gaap Operating Lease Cost
OperatingLeaseCost
360000
us-gaap Lease Cost
LeaseCost
360000
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0800
us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
373000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
755000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
491000
CY2019Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1619000
CY2019Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
181000
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
1438000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
723000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
736000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
488000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1947000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.13
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.06
CY2019Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1038
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Trading Symbol
TradingSymbol
ZIOP
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2019Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
162552963
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2019Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P12M
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
ZIOPHARM ONCOLOGY INC
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Shell Company
EntityShellCompany
false
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
600000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1275000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
240000
CY2018Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
544000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
600000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
370000
CY2019Q1 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
446428
CY2018Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
5462000
us-gaap Dividends Preferred Stock
DividendsPreferredStock
10582000
CY2017 us-gaap Research And Development Arrangement Contract To Perform For Others Description And Terms
ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
Pursuant to the Research and Development Agreement, the Company, Precigen and MD Anderson formed a joint steering committee to oversee and manage the new and ongoing research programs. Under the License Agreement with Precigen, the Company and Precigen agreed that Precigen would no longer participate on the joint steering committee after the date of the License Agreement. As provided under the MD Anderson License, the Company provided funding for research and development activities in support of the research programs under the Research and Development Agreement for a period of three years and in an amount of no less than $15.0 million and no greater than $20.0 million per year.
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Security12b Title
Security12bTitle
Common Stock

Files In Submission

Name View Source Status
0001193125-19-216056-index-headers.html Edgar Link pending
0001193125-19-216056-index.html Edgar Link pending
0001193125-19-216056.txt Edgar Link pending
0001193125-19-216056-xbrl.zip Edgar Link pending
d777738d10q.htm Edgar Link pending
d777738dex103.htm Edgar Link pending
d777738dex311.htm Edgar Link pending
d777738dex312.htm Edgar Link pending
d777738dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ziop-20190630.xml Edgar Link completed
ziop-20190630.xsd Edgar Link pending
ziop-20190630_cal.xml Edgar Link unprocessable
ziop-20190630_def.xml Edgar Link unprocessable
ziop-20190630_lab.xml Edgar Link unprocessable
ziop-20190630_pre.xml Edgar Link unprocessable